drugset / Trial / NCT01639261

A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT

NCT01639261

NaSingle-groupOpen-labelTreatment

Summary

Improvement of quality of life in patients with BO and establishment of a new third line therapy

Timeline

Start
2012-07
Primary completion
2013-12
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon gamma-1b Protein / enzyme biologic 50 ug/m2 Subcutaneous